Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC boosted its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 222.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,927 shares of the company’s stock after purchasing an additional 16,508 shares during the quarter. SG Americas Securities LLC’s holdings in Ionis Pharmaceuticals were worth $836,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Geode Capital Management LLC boosted its position in Ionis Pharmaceuticals by 7.4% during the 3rd quarter. Geode Capital Management LLC now owns 2,668,358 shares of the company’s stock valued at $106,922,000 after purchasing an additional 183,814 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Ionis Pharmaceuticals by 8.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,443,020 shares of the company’s stock valued at $57,807,000 after purchasing an additional 114,914 shares in the last quarter. ARK Investment Management LLC grew its stake in Ionis Pharmaceuticals by 1.7% in the third quarter. ARK Investment Management LLC now owns 1,384,269 shares of the company’s stock valued at $55,454,000 after purchasing an additional 23,244 shares in the last quarter. Two Sigma Advisers LP boosted its stake in shares of Ionis Pharmaceuticals by 3.5% during the 3rd quarter. Two Sigma Advisers LP now owns 1,332,411 shares of the company’s stock worth $53,376,000 after acquiring an additional 45,300 shares in the last quarter. Finally, Groupama Asset Managment boosted its stake in Ionis Pharmaceuticals by 4.1% during the 3rd quarter. Groupama Asset Managment now owns 916,060 shares of the company’s stock valued at $367,000 after purchasing an additional 36,084 shares during the period. 93.86% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Ionis Pharmaceuticals

In other news, CFO Elizabeth L. Hougen sold 8,870 shares of the company’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $32.81, for a total transaction of $291,024.70. Following the transaction, the chief financial officer now owns 107,885 shares in the company, valued at approximately $3,539,706.85. This represents a 7.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Brett P. Monia sold 6,630 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $38.05, for a total transaction of $252,271.50. Following the sale, the chief executive officer now directly owns 167,393 shares of the company’s stock, valued at approximately $6,369,303.65. The trade was a 3.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 57,293 shares of company stock valued at $1,914,820 over the last three months. 2.71% of the stock is owned by insiders.

Ionis Pharmaceuticals Trading Down 3.6 %

Shares of Ionis Pharmaceuticals stock opened at $32.88 on Thursday. The firm’s 50-day moving average price is $35.19 and its two-hundred day moving average price is $40.39. The company has a market capitalization of $5.19 billion, a price-to-earnings ratio of -13.48 and a beta of 0.35. The company has a quick ratio of 8.82, a current ratio of 8.91 and a debt-to-equity ratio of 1.86. Ionis Pharmaceuticals, Inc. has a 12-month low of $31.40 and a 12-month high of $52.49.

Analyst Upgrades and Downgrades

IONS has been the subject of several recent research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $60.00 price target on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Piper Sandler decreased their price objective on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. William Blair restated an “outperform” rating on shares of Ionis Pharmaceuticals in a research report on Friday, December 20th. StockNews.com downgraded Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Finally, Guggenheim reduced their price objective on shares of Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, October 9th. Two analysts have rated the stock with a sell rating, five have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Ionis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $60.65.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.